Last June, Pfizer, the lone U.S. manufacturer of the injections, notified the Food and Drug Administration of an 'impending stock out' that it anticipated would last a year. The company blamed 'an increase in syphilis infection rates as well as competitive shortages.'
The risks of harm to a developing baby from syphilis are so high that experts urge not to delay treatment, even by a day.
Collection
[
|
...
]